Turn Therapeutics ($TTRX) to Ring the Closing Bell at Nasdaq

Pipeline

Inflammation Therapeutics
Pipeline

Turn Therapeutics is a biotechnology company developing a first-in-class, precision, non-systemic immunomodulation platform that targets IL-36 and key downstream cytokines to address high-unmet-need inflammatory diseases, with an initial focus on moderate to severe eczema.

Our Pipeline

Preclinical

Phase 1

Phase 2

Phase 3

GX-03

IL-36α, IL-36γ, IL-31 and IL-4 inhibitor. Non-systemic and non-steroid potentially best-in-class topical
Moderate-to-Severe Eczema (AD)
Q1 2026: Interim Analysis
Q2 2026: Phase 2 Readout
2H 2026: Phase 3 initiation
Onychomycosis
2H 2026: Phase 3 initiation
Psoriasis
Q1 2026: In-Vivo studies initiation

Vaccine Candidate

Targeted Intranasal Thermostable Respiratory Vaccine
Thermostability Validated with 100% of rVSV-MARV recovery at 14 days ambient and 28 days refrigerator temp
rVSV-MARV
Q1 2026: In-vivo Immunogenicity
H1N1-Influenza
Q1 2026: Stability and In-vivo Immunogenicity

Medical Devices

FDA cleared Antimicrobial Surgical Gauze out-licensed
Sterile Collagen Powder out-licensed for $70M+ milestones
  • Westlake Village, CA
  • 1-818-564-4011

Muhammad Zubair

Controller

Zubair, Controller, has 5+ years of accounting and finance management experience in companies ranging from medium-sized companies to pulicly traded multinationals. Zubair is a member of the Institute of Chartered Accountants of Pakistan and holds a Master’s degree in accounting & finance (Equivalent). 

Linkedin

Zuraiz Chaudhary, CPA

Chief Accounting Officer, VP Finance

Zuraiz, VP of Finance and Chief Accounting Officer, is a seasoned finance & accounting executive with more than a decade experience in working with PwC, EY and KPMG.  Zuraiz is a licensed CPA in California and Texas, has a bachelor’s in business administration from Asia-e University (Malaysia), is a member of the Institute of Chartered Accountants of Pakistan. Zuraiz specializes in financial reporting, SOX compliance and internal controls.

Linkedin

Dr. Neil Ghodadra, MD

Chief Medical Officer, Board Director

Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.

Linkedin

Bradley Burnam

Chief Executive Officer & Founder

Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn’s flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn’s first three FDA clearances solo before assembling a skilled team.

Linkedin

Subscribe to the Founder's Blog

Enter your information to subscribe for the latest updates from our Founder’s Blog.

Sign Up for Updates

Enter your information to receive the latest product updates and news from Turn Therapeutics.